{"id":29094,"date":"2026-03-02T06:28:51","date_gmt":"2026-03-02T06:28:51","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/29094\/"},"modified":"2026-03-02T06:28:51","modified_gmt":"2026-03-02T06:28:51","slug":"novo-nordisk-stock-crashes-after-company-cuts-sales-profit-outlook-on-weight-loss-drug-competition","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/29094\/","title":{"rendered":"Novo Nordisk stock crashes after company cuts sales, profit outlook on weight-loss drug competition"},"content":{"rendered":"

Novo Nordisk (NVO<\/a>) stock plunged on Tuesday, down over 21% at the closing bell after the company behind the viral weight-loss drug Wegovy and diabetes treatment Ozempic slashed its sales and profit forecasts.<\/p>\n

In a release early Tuesday, the pharmaceutical giant cut its expected full-year sales growth<\/a> to 8%-14%, down from the 13%-21% it expected to see as of May.<\/p>\n

The company also said it now expects operating profit growth of 10%-16%, down from its previous estimate of 16%-24%.<\/p>\n

Read more about Novo Nordisk’s stock moves and today’s market action.<\/a><\/p>\n

Novo Nordisk attributed the estimate cuts to weaker-than-expected second-half sales forecasts for both Wegovy and Ozempic as the company has had to fend off competition from rivals and copycat “compounder” drugs.<\/p>\n

“For Wegovy in the US, the sales outlook reflects the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition,” the company said in its statement<\/a>. “For Ozempic, the updated outlook is negatively impacted by competition in the US.”<\/p>\n

Rival drugmaker Eli Lilly and Company (LLY<\/a>), which also makes weight-loss drugs like the Danish maker’s Wegovy, was down more than 5% at the closing bell, while competitor Hims & Hers Health (HIMS<\/a>) ended the day up more than 2.5%.<\/p>\n

\"17<\/p>\n

A customs investigator holds a package of Ozempic during the presentation of seized doping agents, drugs, and assets such as cash and gold in a hall on the premises of the Hamburg Customs Investigation Office. (Marcus Brandt\/picture alliance via Getty Images)<\/p>\n

(picture alliance via Getty Images)<\/p>\n

Novo Nordisk’s estimate cuts mark the second time this year that the company has lowered performance expectations, after cutting its 2025 full-year guidance in May<\/a> following weaker-than-expected Q1 sales figures.<\/p>\n

The drugmaker’s share price is down more than 55% over the past year as the company has faced increasing competition from the likes of Hims and Eli Lilly.<\/p>\n

US prescriptions for Eli Lilly’s weight-loss drug Zepbound passed those issued for Novo Nordisk’s Wegovy<\/a> in March, according to Reuters. Eli Lilly also announced in May that its weight-loss drug was more effective<\/a> across several markers in a head-to-head trial between the two.<\/p>\n

In a press release released concurrently Tuesday morning with the lowered estimates announcement, Novo Nordisk said that Mike Doustdar, the company’s executive vice president of international operations, will be the drugmaker’s new president and CEO<\/a> as of Aug. 7.<\/p>\n

Doustdar replaces Lars Fruergaard J\u00f8rgensen, whose outster was announced in May after the company’s stock price spent a year plunging downward.<\/p>\n

\"StockStory<\/a><\/p>\n

StockStory aims to help individual investors beat the market.<\/p>\n

Jake Conley is a breaking news reporter covering US equities for Yahoo Finance. Follow him on X at @byjakeconley or email him at jake.co<\/a>nley@yahooinc.com<\/a>.<\/p>\n

Click here for the latest stock market news and in-depth analysis, including events that move stocks<\/a><\/p>\n

Read the latest financial and business news from Yahoo Finance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk (NVO) stock plunged on Tuesday, down over 21% at the closing bell after the company behind…\n","protected":false},"author":2,"featured_media":29095,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2042,18205,276,18204,272,4165,18202,18203,3388,277],"class_list":{"0":"post-29094","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-competition","9":"tag-diabetes-treatment","10":"tag-eli-lilly","11":"tag-hamburg-customs-investigation-office","12":"tag-novo-nordisk","13":"tag-operating-profit","14":"tag-profit-forecasts","15":"tag-sales-forecasts","16":"tag-weight-loss-drug","17":"tag-weight-loss-drugs"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/29094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=29094"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/29094\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/29095"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=29094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=29094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=29094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}